Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

WBZ-TV's Dr. Mallika Marshall reports that drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its ...

The Trump administration is trying to continue its rapid pace of policy changes and reshaping of the U.S. economy.

The Colorado Sun: Colorado Mental Health Providers Say They Were “Betrayed” By Medicaid Behavioral health providers stepped up to offer new services to fill a gap, but the promise of higher ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Novo Nordisk and Eli Lilly , the leaders in the highly lucrative ... to align with what other countries pay that analysts and legal experts said would be difficult to implement.

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...

Houston-based Empower Pharmacy has rapidly expanded over the past decade. Now a competitor is suing Empower, alleging its ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...